L.P. Ra Capital Management Acquires LENZ Shares
Insiders at LENZ, including L.P. Ra Capital Management, purchased shares recently.
Key Points
- L.P. Ra Capital Management bought 22,100 shares of LENZ on June 15, 2026.
- LENZ's stock is trading at $6.77, with insider buying activity noted.
- Analysts from Citigroup and HC Wainwright & Co. maintain a 'buy' rating on LENZ.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
L.P. Ra Capital Management recently acquired 22,100 shares of LENZ on June 15, 2026. This insider buying activity comes as LENZ shares are trading at $6.77, highlighting interest in the company despite its current market challenges.
Insider Buying and Selling at LENZ Therapeutics, Inc.
Several insiders, including Zachary Scheiner, Frederic Guerard, James McCollum, Shelley Thunen, Kimberlee Drapkin, and Jeffrey George, each purchased 22,100 shares of LENZ on June 15, 2026. These transactions were not part of a pre-planned 10b5-1 trading plan, indicating a direct interest in increasing their holdings.
Other Institutional Activity in LENZ
Versant Venture Management, LLC significantly increased its LENZ holdings by 2,656,888 shares, ending with 5,313,776 shares valued at about $48.6 million. Meanwhile, BlackRock, Inc. added 284,817 shares, bringing its total to 1,976,823 shares worth approximately $18.1 million. In contrast, FMR LLC reduced its holdings by 104,934 shares, resulting in 3,597,784 shares valued at around $32.9 million.
LENZ Therapeutics, Inc. Stock Up 32.5%
LENZ shares are currently trading at $6.77. The stock's performance is under scrutiny as insiders and institutions adjust their positions. While specific financial metrics like P/E ratio and market cap are not available, the stock's recent insider and institutional activity suggests a dynamic interest in its potential.
Analysts Set New Price Targets
On May 13, 2026, Citigroup maintained its 'buy' rating on LENZ with a price target of $20. Similarly, HC Wainwright & Co. reiterated a 'buy' rating with a target of $38 on May 12, 2026. However, Piper Sandler downgraded the stock to 'hold' with a $12 price target on the same day. The consensus among analysts remains positive, with a general recommendation to 'buy' and varied price targets reflecting differing outlooks on the stock's future performance.
Bottom Line
The recent insider purchases by L.P. Ra Capital Management and other insiders signal confidence in LENZ's future. While the stock trades at $6.77, the activity suggests potential growth or strategic developments. Analysts maintain a generally positive outlook, although opinions vary, reflecting the stock's uncertain yet promising situation. As always, insider transactions are backward-looking and may not reflect current positions.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.